Printer Friendly

Bordetella pertussis, Finland and France.

We used pulsed-field gel electrophoresis analysis and genotyping to compare clinical isolates of Bordetella pertussis recovered since the early 1990s in Finland and France, 2 countries with similar histories of long-term mass vaccination with whole-cell pertussis vaccines. Isolates from both countries were similar genetically but varied temporally.


The introduction of whole-cell pertussis vaccines (wP) from the 1940s to the 1960s in many countries resulted in a dramatic decrease in illness and death from pertussis. However, pertussis remains a considerable public health problem worldwide. Indeed, the disease continues to be endemic in vaccinated populations in Europe, Australia, Canada, and the United States, with cyclic increases at 3- to 5-year intervals, despite high vaccination coverage (1,2). One of the major causes is waning of vaccine-induced immunity with time (1,3), but increased disease surveillance and use of biologic diagnosis are also implicated. However, changes in the agent of the disease, Bordetella pertussis, are of some concern. This bacterium expresses adhesins such as filamentous hemagglutinin, pertactin, fimbriae (FIM), and toxins such as pertussis toxin, and adenylate cyclase-hemolysin (4). Recently, circulating isolates were found to differ from the strains used for the wP vaccines in the world (5-13). These observed changes might modify the properties of the isolates and affect the efficacy of pertussis vaccines.

In Europe, heterogeneity is high in epidemic situations with respect to wP vaccines used and vaccination history and strategy. However, Finland and France have implemented similar mass wP vaccination programs with high coverage for several decades. Since 1952, children in Finland have been vaccinated with combined diphtheria-tetanus wP vaccine (DTwP) at 3, 4, and 5 months and from 20 to 24 months of age. The wP vaccine contains 2 strains and has remained unchanged since 1976. Since 1959, children in France have been vaccinated with DTwP-inactivated polio vaccine at 3, 4, and 5 months and from 16 to 18 months of age. The vaccine calendar for primary vaccination was changed to 2, 3, and 4 months of age in 1995. The same wP vaccine, composed of 2 strains, has been used for >40 years. In both Finland and France, incidence of pertussis has increased and the disease has shifted to older age groups, especially adolescents and adults. The cycles of pertussis disease are observed every 3-5 years (5,13). The aim of this study was to analyze and compare the isolates circulating in the 2 European countries with long-term and intensive vaccination.

B. pertussis isolates were selected from collections of the Finnish Pertussis Reference Laboratory of the National Public Health Institute (Turku, Finland) and the French Pertussis National Center of Reference (Paris, France). Of the 503 Finnish isolates recovered from 1991 to 2004, 64 were selected either because they represent all available isolates from 1 community (Paimio) or they were recovered from a geographic area as wide as possible. In addition, 6 isolates from a school outbreak that occurred in Heinavesi (Finland) in 1982 were included to study the changes over time. Of the 1,049 French isolates recovered from 1991 to 2004, we selected 61 because they are representative of the French collection from a temporal and geographic viewpoint and they correlate with the different cycles of pertussis observed in France and Finland.

All Finnish and French isolates showed a high similarity with a minimum of 80.3% overall relatedness by using pulsed-field gel electrophoresis (PFGE) analysis after digestion of B. pertussis genomic DNA with XbaI restriction enzyme (14) (Appendix Figure, available online at Most Finnish and French isolates fell into PFGE groups III, IV, and V (Appendix Figure and Figure, panel A) corresponding to the isolates circulating in Europe from 1999 to 2001 (14). A new PFGE group (VII) was identified among Finnish isolates recovered in 2004 (Appendix Figure and Figure, panel A). This new profile, with 97.3% level of relatedness (Appendix Figure), might represent an emerging group. The new profile was further confirmed with PFGE by using the second restriction endonuclease SpeI (data not shown), as previously recommended (5,14). We cannot say whether PFGE VII isolates are actually emerging or whether evidence for their emergence is anecdotal, as is the case with French PFGE VI isolates, which represent only 0.6% of French isolates (data not shown).

We previously showed that the major PFGE group circulating in Europe from 1999 to 2001 is group IV (14). In France and in Finland, the PFGE group IV was overrepresented from 1992 to 2004 with 85.3% level of relatedness, confirming the limited polymorphism of B. pertussis. PFGE group IV was subdivided into 3 subgroups, [alpha], [beta], and [gamma], whose frequencies varied between countries (14). In our study, we show that, as in France (5) the PFGE groups of the isolates circulating in Finland vary temporally with the cycles of the disease (Appendix Figure and Figure, Panel A). However, the frequency of the isolate subgroups circulating in Finland and France was different. In fact, the major subgroup detected in Finland between 1992 and 1999 was IV[gamma]; since 2000, subgroups IV[alpha] and IV[beta] have been found (Figure, Panel A). This circumstance is well illustrated among the isolates recovered in Paimio, where 99% of isolates with IV[gamma] were circulating in 1992 whereas, in 2004, 42% of subgroup IV[beta], 33% of subgroup IV[alpha], 25% of the new group VII, and none of IV[gamma] were circulating in Paimio. Subgroups IV[alpha] and [beta], absent from 1992 to 1994, are now circulating. However, subgroup IV[alpha] is not a new subgroup in Finland since the 6 isolates collected in Heinavesi in 1982 exhibit this profile (Appendix Figure).

The analysis also included genotyping of the genes encoding pertussis toxin SI subunit (ptxA) and pertactin (prn) and serotyping of FIM, performed as described previously (5,13). The sequence of ptxA is the same (ptxA allele type 1) for all Finnish and French isolates. The same types of prn alleles are also harbored by Finnish and French isolates (Appendix Figure). The emergence of isolates harboring ptxA1 and prn2 or prn3 alleles in both countries might be explained by the fact that the wP vaccine strains used in both countries harborptxA2 or A4 and prn1 alleles (13,15). A similar hypothesis might be proposed for the expression of FIM. In fact, most of the Finnish isolates collected from 1991 to 2004 express FIM2, whereas in France most of the isolates express FIM3 (Figure, Panel B). The differences in the expression of FIM between Finnish and French isolates might reflect the difference in strains used for Finnish and French wP vaccines. The Finnish wP vaccine contains 2 strains expressing FIM2,3 and FIM3, whereas the French wP vaccine includes 2 strains expressing FIM2,3 and FIM2 (13,15). A marked shift of predominant serotype from FIM2 to FIM3 has been observed in Finland since 1999, although the wP vaccine remained the same. The emergence of isolates with FIM3 and PFGE subgroup IV[beta], a new subgroup found in Finland, might be due to the increase in the frequency of this subgroup in the neighboring countries and the increased mobility of people within the European Union in the last decades.

We show that the B. pertussis isolates circulating in 2 countries with a long history of wP vaccination are genetically close. In the 2 countries, similar PFGE groups and subgroups are present, but their frequencies were different in the 1990s. Further, the subgroup emerging according to the cycles of pertussis in each country varies. The difference observed in frequency of subgroups could be due to herd immunity or human density of the populations concerned. Does this herd immunity vary depending on the human genetic population concerned or are the vaccine strains used expressing similar factors but not at the same level (e.g., FIM2 vs. FIM3)? This question needs further investigation.

These 2 countries have started using acellular pertussis vaccines, France since 2002 and Finland since 2005. Continued monitoring of the circulating isolates will be important.

We thank the European Commission of Life Program (QLK2-CT-2001-01819, EUpertstrain), GlaxoSmithKline, and Sanofi-Pasteur laboratories for supporting this work financially. This work was also financially supported by Institut Pasteur Foundation and FRE-CNRS 2849 for France and the Special Governmental Fund for University Hospitals (EVO) for Finland.

Dr Caro is assistant director of the French National Center of Reference of Whooping Cough and Other Bordetelloses and researcher in the Molecular Prevention and Therapy of Human Diseases Unit, Institut Pasteur, Paris, France. Her research interests focus on the molecular evolution of Bordetella in relation to clinical and public health problems, comparative genomic analysis, and new molecular diagnostic methods.


(1.) Wirsing von Konig CH, Halperin S, Riffelmann M, and Guiso N. Pertussis of adults and infants. Lancet Infect Dis.2002;2:744-50.

(2.) Tanaka M, Vitek CR, Pascual FB, Bisgard KM, Tate JE, and Murphy TV. Trends in pertussis among infants in the United States, 1980-1999. Jama.2003;290:2968-75.

(3.) Forsyth K, Tan T, von Konig CH, Caro JJ, and Plotkin S. Potential strategies to reduce the burden of pertussis. Aims, scope and findings of the global pertussis initiative. Pediatr Infect Dis J. 2005;24:S69-74.

(4.) Mattoo S, and Cherry JD. Molecular pathogencsis, epidemiology, and clinical manifestations of respiratory infections due to Bordetella-pertussis and other Bordetella subspecies. Clin Microbiol Rev.2005;18:326-82.

(5.) Weber C, Boursaux-Eude C, Coralie G, Caro V, and Guiso N. Polymorphism of Bordetellapertussis isolates circulating the last ten years in France, where a single effective whole-cell vaccine has been used for more than thirty years. J. Clin. Microbiol.2001;39:4396-4403.

(6.) Mooi FR, van Oirschot H, lteuvehnan K, van der Heide HGJ, Gaastra W, and Willems RJL. Polymorphism in the Bordetella pertussis virulence factors P.69/pertactin and pertussis toxin in the Netherlands: Temporal trends and evidence for vaccine-driven evolution. Infect. Immun.1998;66:670-5.

(7.) Gzyl A, Augustynowicz E, Van Loo I, and Slusarczyk J. Temporal nucleotide changes in pertactin and pertussis toxin genes in Bordetella pertussis strains isolated from clinical cases in Poland. Vaccine.2002;20:299-303.

(8.) Fry NK, Neal S, Harrison TG, Miller E, Matthews R, and George RC. Genotypic variation in the Bordetella pertussis Virulence Factors pertactin and pertussis toxin in historical and recent clinical isolates in the United Kingdom. Infect. Immun.2001;69:5520-8.

(9.) Mastrantonio P, Spigaglia P, van Oirschot H, van der Heidc HG J, Heuvelman K, Stefanelli P, et al. Antigenic variants in Bordetella pertussis strains isolated from vaccinated and unvaccinated children. Microbiol.1999;145:2069-75.

(10.) Poynten M, McIntyre PB, Mooi FR, Heuvehnan KJ, and Gilbert GL. Temporal trends in circulating Bordetella pertussis strains in Australia. Epidemiol Infect.2004;132:185-93.

(11.) Peppier MS, Kuny S, Nevesinjac A, Rogers C, De Moissac YR, Knowles K, et al. Strain variation among Bordetella pertussis isolates from Quebec and Alberta provinces of Canada from 1985 to 1994. J Clin Microbiol.2003;41:334-47.

(12.) Hardwick TH, Cassiday P, Weyant RS, Bisgard KM, and Sanden GN. Changes in predominance and diversity of genomic subtypes of Bordetella pertussis isolated in the United States, 1935 to 1999. Emerging Infect. Dis.2002;8:44-9.

(13.) Elomaa A, Advani A, Donnelly D, Antila M, Mertsola J, Hallander H, et al. Strain variation among Bordetella permssis isolates in Finland, where the whole-cell pertussis vaccine has been used for 50 years. J Clin Microbiol.2005;43:3681-7.

(14.) Caro V, Njamkepo E, Van Amersfoorth SC, Mooi FR, Advani A, Hallander HO, et al. Pulsed-field gel electrophoresis analysis of Bordetella pertussis populations in various European countries with different vaccine policies. Microbes Infect.2005;7:976-82.

(15.) Njamkepo E, Rimlinger F, Thiberge S, and Guiso N. Thirty-five years' experience with the whole-cell pertussis vaccine in France: vaccine strains analysis and immunogenicity. Vaccine.2002; 20:1290-4.

Valerie Caro, * Annika Elomaa, ([dagger]) Delphine Brun, * Jussi Mertsola, ([dagger]) Qiushui He, ([dagger]) and Nicole Guiso *

* Institut Pasteur, FRE-CNRS 2849, Paris, France; and ([dagger]) National Public Health Institute and University of Turku, Turku, Finland

Address for correspondence: Valdrie Caro, lnstitut Pasteur, Unite PTMMH, FRE-CNRS 2849, National Center of Reference of Whooping Cough and Other Bordetelloses, 25 Rue du Dr Roux, 75724 Paris CEDEX 15, France, email:

The opinions expressed by authors contributing to this journal do not necessarily reflect the opinions of the Centers for Disease Control and Prevention or the institutions with which the authors are affiliated.
COPYRIGHT 2006 U.S. National Center for Infectious Diseases
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2006, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:DISPATCHES; infectious diseases research
Author:Guiso, Nicole
Publication:Emerging Infectious Diseases
Geographic Code:4EUFI
Date:Jun 1, 2006
Previous Article:Acanthamoeba encephalitis in patient with systemic lupus, India.
Next Article:Guillain-Barre syndrome, greater Paris area.

Related Articles
Vaccine confers pertussis protection.
New pertussis vaccines safer, more effective.
When pertussis is not whooping cough.
Vaccine Verity.
Rapid identification of Bordetella pertussis pertactin gene variants using LightCycler real-time polymerase chain reaction combined with melting...
Changes in predominance and diversity of genomic subtypes of bordetella pertussis isolated in the United States, 1935-1999. (Research).
Persistent cough: pertussis rises in young adults and infants.
Bordetella petrii clinical isolate.

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters